Risks of hypomagnesaemia and increased risk of fracture with long-term PPI use
23rd April 2012
The UK Medicines and Healthcare products Regulatory Agency (MHRA) have alerted healthcare professionals of the possible risks of hypomagnesaemia and also increased fracture risk with long-term Proton Pump Inhibitor (PPI) use (generally >1year) in their latest Drug Safety Update publication.
- Improving the quality of care in the last days of life: A practical guide to getting the medications right
- NICE End of life care for infants, children and young people
- NICE evidence summary for fentanyl transdermal patient controlled system
- New naproxen suspension available in UK
- Neuropathic pain: pregabalin and gabapentin prescribing
- Topical miconazole interaction with warfarin
- RPS guidance for the prescribers of Specials
- IPC5 now available!
- e-learning Indian palliative care course
- Epistatus 10mg/mL oromucosal solution batch recall